CG Oncology, Inc.
CGONDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
3
Next Catalyst
Aug 14, 2026
16dMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
How CGON's past catalysts played out
Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
CG0070
Non Muscle Invasive Bladder Cancer
Ivaltinostat
Metastatic Pancreatic Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cretostimogene Grenadenorepvec | Phase 3 | High-Risk Non-Muscle-Invasive Bladder Cancer | - | - |
CG0070 | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Ivaltinostat | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CG Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in CG Oncology, Inc.'s (CGON) pipeline across Phase 3, Phase 2. Its lead program is Cretostimogene Grenadenorepvec (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CG Oncology, Inc.'s next FDA catalyst?→
CG Oncology, Inc.'s (CGON) next tracked catalyst is a Earnings expected August 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CGON biotech catalysts?→
Add CGON to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CG Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.